Objectives: To characterise the developmental trajectories of arithmetic, reading comprehension and spelling abilities of very preterm and full-term born children during primary school.
Design: A longitudinal analysis of academic performance data of very preterm and full-term born children was performed. Academic performance was assessed in grade 1-6 of primary school using a pupil monitoring system, with 11 measurements of arithmetic and spelling performance and 7 measurements of reading comprehension. Data were analysed using mixed-effects models.
Patients: A Dutch cohort of 52 very preterm children born between 2001-2003 and 58 full-term controls participated.
Results: No group-by-time interactions were found for any of the academic domains, indicating no differences in progress between groups. Through the course of primary school, very preterm born children scored on average 0.53 SD lower on arithmetic (95% CI -0.71 to -0.35, p<0.001), 0.31 SD on reading comprehension (95% CI -0.48 to -0.14, p<0.001) and 0.21 SD on spelling (95% CI -0.37 to -0.05, p=0.01) compared with full-term peers.
Conclusions: This is the first longitudinal study to show that the academic difficulties of very preterm born children persisted during primary school. Their progression was similar to full-term born peers, suggesting intact learning abilities. This provides opportunities for interventions to improve the academic outcomes of very preterm born children.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1136/archdischild-2018-315028 | DOI Listing |
Children (Basel)
January 2025
School of Health Sciences, College of Health and Medicine, University of Tasmania, Launceston, TAS 7248, Australia.
Background: The period following childbirth is marked by dynamic changes in maternal physiology and the growth trajectory of the newborn. We aimed to elucidate the changes and associations in body composition of infants and their mothers during the first year postpartum.
Methods: This pilot study assessed infant body composition using the PEA POD air displacement plethysmography (ADP) system (birth-6 months) and deuterium dilution (9-12 months).
Children (Basel)
January 2025
Department of Pediatrics, Kaohsiung Chang Gung Memorial Hospital, College of Medicine, Chang Gung University, Kaohsiung 83301, Taiwan.
Background/objectives: This cohort study aimed to establish a correlation between salivary cytokines and retinopathy of prematurity (ROP) in premature neonates. Additionally, we sought to identify a minimally invasive method for cytokine detection in this population.
Methods: We recruited premature neonates born at less than 34 weeks gestational age (GA), with no history of maternal or neonatal infections.
Children (Basel)
January 2025
Pediatric Research Center, New Children's Hospital, University of Helsinki, Helsinki University Hospital, 00290 Helsinki, Finland.
Background: Recombinant growth hormone (rhGH) has been used since 1985 to treat growth hormone (GH)-induced short stature, typically associated with transient adverse events. However, lipoatrophy, characterized by irreversible damage to subcutaneous fat, was first reported in 1999 and linked to antibody formation. In 2021, localized lipoatrophy was observed in 14.
View Article and Find Full Text PDFChildren (Basel)
January 2025
Division of Neonatology, Department of Pediatrics, Emory University and Children's Healthcare of Atlanta, Atlanta, GA 30322, USA.
In recent years, significant advancements in respiratory and nutritional care have markedly improved the survival rates of preterm infants and enhanced long-term health outcomes. Despite these improvements, emerging research highlights the lasting impacts of early growth patterns on an individual's health trajectory. Adults born prematurely face a higher incidence of health issues related to their early birth.
View Article and Find Full Text PDFChildren (Basel)
December 2024
Research Area for Innovative Therapy in Endocrinology, Bambino Gesù Children Hospital, IRCCS, 00165 Rome, Italy.
Before 1985, growth hormone (GH) was extracted from human pituitaries, and its therapeutic use was limited to children with severe GH deficiency (GHD). The availability of an unlimited amount of recombinant GH (rhGH) allowed for investigating the efficacy of its therapeutic use in a number of conditions other than GHD. Nowadays, patients with Turner syndrome, deficiency, Noonan syndrome, Prader-Willi syndrome, idiopathic short stature, chronic kidney disease, and children born small for gestational age can be treated with rhGH in order to improve adult height.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!